The case for selective use of pre-operative chemotherapy for hepatic colorectal metastases: More is not always better: Editorial

Annals of Surgical Oncology

Volumn 16, Issue 8, 2009, Pages 2086-2088

  Karakousis, Giorgos ^a   Fong, Yuman ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADJUVANT CHEMOTHERAPY; CANCER GROWTH; CLINICAL TRIAL; COLORECTAL CANCER; EDITORIAL; HEALTH CARE COST; HEPATIC COLORECTAL METASTASIS; HUMAN; LIVER RESECTION; METASTASIS; POSTOPERATIVE CARE; PREOPERATIVE CARE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; PREOPERATIVE CARE;

EID: 67650970110     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-009-0539-9     Document Type: Editorial

References (13)

1. Y Fong RL Sun W Jarnagin LH Blumgart 1999 An analysis of 412 cases of hepatocellular carcinoma at a Western center Ann Surg 229 790 799
2. Y Fong J Fortner RL Sun MF Brennan LH Blumgart 1999 Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases Ann Surg 230 309 318
3. R Adam V Delvart G Pascal 2004 Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival Ann Surg 240 644 657
4. Reddy S, Zorzi D, Lum YW, et al. Timing of multimodality therapy for resectable synchronous colorectal liver metastases: a retrospective multi-institutional analysis. Ann Surg Oncol. DOI: 10.1245/s10434-008-0181-y.
5. J Tabernero CE Van E az-Rubio A Cervantes 2007 Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer J Clin Oncol 25 5225 5232
6. B Nordlinger H Sorbye B Glimelius 2008 Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial Lancet 371 9617 1007 1016
7. Nikfarjam M, Shereef S, Kimchi E, et al. Survival outcomes of patients with colorectal liver metastases following hepatic resection or ablation in the era of effective chemotherapy. Ann Surg Oncol. DOI: 10.1245/s10434-008-225-3.
8. F Bibeau E Lopez-Crapez F Di Fiore S Thezenas M Ychou F Blanchard 2009 Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan J Clin Oncol 27 7 1122 1129
9. Y Fong DJ Bentrem 2006 CASH (chemotherapy-associated steatohepatitis) costs Ann Surg 243 8 9
10. Khan AZ, Morris-Stiff G, Makuuchi M. Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases. J Hepatobiliary Pancreat Surg. (in press).
11. R Martin P Paty Y Fong 2003 Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastasis J Am Coll Surg 197 233 241
12. R Park M Gonen N Kemeny 2007 Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents J Am Coll Surg 204 753 761
13. G Portier D Elias O Bouche 2006 Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial J Clin Oncol 24 4976 4982